TNFSF10 and cancer: Our simulations clearly show that alternating pro-apoptotic treatments with pro-necroptotic treatments is a sequence that improves cancer drug response (Fig. 6A,B), revealing that sensitive cells to necroptosis represent a major part of the population tolerant to Apoptosis in PSM1D topology 3 (Fig. 6A) and that sensitive cells to Necroptosis grow faster after TRAIL treatment is stopped.